Literature DB >> 11339541

Vaccination against cytomegalovirus.

S A Plotkin1.   

Abstract

Like varicella zoster virus (VZV), human cytomegalovirus (HCMV) causes disease after both primary and recurrent infections. The former is more serious, particularly in pregnant women, who may transmit the virus to their offspring, with a high risk of mental retardation and deafness. Various experimental vaccines are in development, ranging from live, attenuated HCMV, subunit envelope glycoprotein, poxvirus vectors with CMV genes inserted, and plasmid DANN.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11339541     DOI: 10.1007/978-3-7091-6259-0_13

Source DB:  PubMed          Journal:  Arch Virol Suppl        ISSN: 0939-1983


  7 in total

Review 1.  Synthetic DNA approach to cytomegalovirus vaccine/immune therapy.

Authors:  Stephan J Wu; Daniel O Villarreal; Devon J Shedlock; David B Weiner
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

2.  Congenital cytomegalovirus infection in high-risk Canadian infants: Report of a pilot screening study.

Authors:  Wendy Vaudry; Rhonda J Rosychuk; Bonita E Lee; Po Yin Cheung; Xl Pang; Jutta K Preiksaitis
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 3.  Translational mini-review series on infectious disease: congenital cytomegalovirus infection: 50 years on.

Authors:  J Hassan; J Connell
Journal:  Clin Exp Immunol       Date:  2007-08       Impact factor: 4.330

4.  Congenital Cytomegalovirus Infection.

Authors:  James F. Bale; Lonnie Miner; Susan J. Petheram
Journal:  Curr Treat Options Neurol       Date:  2002-05       Impact factor: 3.972

5.  Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus.

Authors:  Jie Zhong; Michael Rist; Leanne Cooper; Corey Smith; Rajiv Khanna
Journal:  PLoS One       Date:  2008-09-22       Impact factor: 3.240

6.  Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand.

Authors:  Adriana Tomić; Pavankumar R Varanasi; Mijo Golemac; Suzana Malić; Peggy Riese; Eva M Borst; Eva Mischak-Weissinger; Carlos A Guzmán; Astrid Krmpotić; Stipan Jonjić; Martin Messerle
Journal:  PLoS Pathog       Date:  2016-12-01       Impact factor: 6.823

7.  Viral vaccine meeting held in Barcelona, October 25-28, 2003.

Authors:  A C M Boon; S Plotkin; G F Rimmelzwaan; A D M E Osterhaus
Journal:  Vaccine       Date:  2004-03-29       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.